Translate ideas into impact
Explore current openings and get ready to prove that impossible isn’t.Unlimit with us
Our founder and CEO, Sean McClain, spoke with Drug Discovery News about how Absci combines engineered E. coli with artificial intelligence to design effective, quality protein- and antibody-based drug candidates. Read more.
On Thursday, July 22, 2021, Absci debuted on Wall Street with an IPO, raising about $200 million in the name of further developing our AI-powered Integrated Drug Creation Platform™ to identify biologics and help speed the development of new treatments.
Our public debut generated buzz among both the business and life sciences communities. For more information, check out the list of the top ten news articles covering the IPO:
Sean McClain, CEO and founder of Absci, spoke with TechCrunch about the company’s recent accomplishments and journey to IPO. Read more.
Absci CEO and Founder Sean McClain explains his company’s outlook and his experience going public via an IPO. Read more.
Totient, a biotech company harnessing human immune responses to identify novel antibodies and their therapeutic targets, has been acquired by Absci. Read more.
Absci CEO and Founder Sean McClain spoke with GEN about how its Escherichia coli platforms are engineered to defy known cell line limitations and enable high-titer scale-up of challenging biologics. Read more.
Endpoints News names Sean McClain, CEO and founder of Absci, to its 20 Under Forty in Biopharma list. Read more.
AbSci has secured $125 million in financing that it plans to use to further develop its artificial intelligence platform for creating synthetic biology drugs. Read more.
AbSci raised an additional $65 million to help grow its synthetic biology platform for discovering and manufacturing complex biological molecules such as antibodies and insulin. Read more.